THC-based drug eliminates PTSD nightmares in a third of patients — Read on ScienceDaily — mente e cervello
After ten weeks of treatment, more than a third of patients with PTSD no longer experienced recurring trauma-related nightmares.
After ten weeks of treatment, more than a third of patients with PTSD no longer experienced recurring trauma-related nightmares.
An observational analysis of 85,000 people suggests that sleeping more at weekends reduces some risks linked to sleep deprivation.
A study links three cardiovascular health factors between ages 45 and 65 to nearly 13 extra years of life without dementia.
Preliminary results from a small group of patients suggest psilocybin could help initiate recovery from anorexia.
The US FDA approves the first bevacizumab formulation dedicated to the eye, after 20 years of off-label repackaged use for wet macular degeneration.
An Indian study shows that not replacing the aortic valve during surgery can ensure good survival while avoiding lifelong anticoagulants.
Uganda's health minister has announced the official end of the country's Ebola outbreak, following a surveillance period with no new cases.
A study identifies genetic variants linked to fibromyalgia risk, paving the way for earlier diagnosis.
Among 517 Chinese students, exercise is associated with stronger socio-emotional skills, mediated by peer relationships and self-efficacy.
The WHO's 2022-2030 report documents measurable results in reducing HIV, hepatitis and STIs worldwide, with data on treatment coverage and diagnosis.
Fosun Health has secured regulatory approval for the first CAR-T therapy aimed at solid tumours rather than blood cancers alone.
The implant for age-related macular degeneration has received regulatory approval for clinical use.
The FDA has approved Outlook Therapeutics' Lytenava (bevacizumab-vikg) for age-related macular degeneration.
A review in Nature shows how evolutionary theory can guide decisions on when to treat fever, with implications for medicine and agriculture.
The US agency has authorised the first version of bevacizumab designed specifically for wet AMD.